Interventional Cardiology Devices | US | 2018 | Market Analysis

An increasingly cost-conscious US health care landscape—owing to more stringent reimbursement and the roll-out of MACRA—has placed substantial downward pressure on the large, yet contracting US IC device market.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in the US, with market projections across a 10-year period.

Continuing innovation in coronary stent technology will be a primary driver of the US IC market, despite setbacks with BVS and immense pricing pressures.

How will next-generation DES shape the US coronary stent market through 2026?

What is the outlook of the BVS segment following the withdrawal of Abbott Laboratories’ Absorb?

Will the continued dominance of DES drive BMS to obscurity?

Which emerging technologies and competitors exist in the coronary stent market?

Recent and upcoming changes to the US health care landscape continue to impact the US IC market.

How will these changes the health care system affect the IC device market?

What are the implications of these changes and how can competitors respond and shift their strategies?

How can recent clinical trial results be leveraged to obtain a competitive advantage?

Despite continued overall market contraction, a number of segments, indicated for complex or difficult to treat lesions, continue to offer growth opportunities.

How has the health care landscape affected the adoption specialized IC products?

What is the opportunity within the high-risk and complex lesion patient populations within the IC market?